Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

被引：424

作者：

Zak, Krzysztof M. ^{[1
,2
]}

Kitel, Radoslaw ^{[2
,3
]}

Przetocka, Sara ^{[1
,2
]}

Golik, Przemyslaw ^{[1
,2
]}

Guzik, Katarzyna ^{[3
]}

Musielak, Bogdan ^{[3
]}

Domling, Alexander ^{[4
]}

Dubin, Grzegorz ^{[1
,2
]}

Holak, Tad A. ^{[2
,3
,5
]}

机构：

[1] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, PL-30387 Krakow, Poland

[2] Jagiellonian Univ, Malopolska Ctr Biotechnol, PL-30387 Krakow, Poland

[3] Jagiellonian Univ, Dept Organ Chem, PL-30060 Krakow, Poland

[4] Univ Groningen, Dept Drug Design, NL-9713 AV Groningen, Netherlands

[5] Max Planck Inst Biochem, D-82152 Martinsried, Germany

来源：

STRUCTURE | 2015年 / 23卷 / 12期

关键词：

CD8; T-CELLS; ANTI-PD-L1; ANTIBODY; CRYSTAL-STRUCTURE; BLOCKADE; INHIBITORS; MPDL3280A; RESPONSES; BLADDER; DESIGN; SAFETY;

D O I：

10.1016/j.str.2015.09.010

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Targeting the PD-1/PD-L1 immunologic checkpoint with monoclonal antibodies has recently provided breakthrough progress in the treatment of melanoma, non-small cell lung cancer, and other types of cancer. Small-molecule drugs interfering with this pathway are highly awaited, but their development is hindered by insufficient structural information. This study reveals the molecular details of the human PD-1/PD-L1 interaction based on an X-ray structure of the complex. First, it is shown that the ligand binding to human PD-1 is associated with significant plasticity within the receptor. Second, a detailed molecular map of the interaction surface is provided, allowing definition of the regions within both interacting partners that may likely be targeted by small molecules.

引用

页码：2341 / 2348

页数：8

共 50 条

[41] PD-1/PD-L1 Axis in Lung Cancer [J].

Santini, Fernando C. ;

Hellmann, Matthew D. .

CANCER JOURNAL, 2018, 24 (01) :15-19

[42] PD-1/PD-L1 Inhibitors in Cervical Cancer [J].

Liu, Yuncong ;

Wu, Li ;

Tong, Ruizhan ;

Yang, Feiyue ;

Yin, Limei ;

Li, Mengqian ;

You, Liting ;

Xue, Jianxin ;

Lu, You .

FRONTIERS IN PHARMACOLOGY, 2019, 10

[43] Mechanisms of Resistance to PD-1 and PD-L1 Blockade [J].

Nowicki, Theodore S. ;

Hu-Lieskovan, Siwen ;

Ribas, Antoni .

CANCER JOURNAL, 2018, 24 (01) :47-53

[44] Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression [J].

Saito, Hiroaki ;

Kono, Yusuke ;

Murakami, Yuki ;

Shishido, Yuji ;

Kuroda, Hirohiko ;

Matsunaga, Tomoyuki ;

Fukumoto, Yoji ;

Osaki, Tomohiro ;

Ashida, Keigo ;

Fujiwara, Yoshiyuki .

ANTICANCER RESEARCH, 2018, 38 (01) :107-112

[45] Combination Strategies PD-1/PD-L1 Antagonists [J].

Sznol, Mario .

CANCER JOURNAL, 2018, 24 (01) :54-57

[46] PD-1/PD-L1 checkpoint in hematological malignancies [J].

Annibali, O. ;

Crescenzi, A. ;

Tomarchio, V. ;

Pagano, A. ;

Bianchi, A. ;

Grifoni, A. ;

Avvisati, G. .

LEUKEMIA RESEARCH, 2018, 67 :45-55

[47] Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status [J].

Yang, Wen ;

Lu, Yan-Ping ;

Yang, Yi-Zhou ;

Kang, Jia-Rui ;

Jin, Yi-Duo ;

Wang, Hong-Wei .

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2017, 43 (10) :1602-1612

[48] PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy [J].

Bocanegra, Ana ;

Blanco, Ester ;

Fernandez-Hinojal, Gonzalo ;

Arasanz, Hugo ;

Chocarro, Luisa ;

Zuazo, Miren ;

Morente, Pilar ;

Vera, Ruth ;

Escors, David ;

Kochan, Grazyna .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (16) :1-17

[49] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer [J].

Monneur, Audrey ;

Goncalves, Anthony ;

Bertucci, Francois .

BULLETIN DU CANCER, 2018, 105 (03) :261-272

[50] Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies? [J].

Konstantinidou, Markella ;

Zarganes-Tzitzikas, Tryfon ;

Magiera-Mularz, Katarzyna ;

Holak, Tad A. ;

Domling, Alexander .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2018, 57 (18) :4840-4848

← 1 2 3 4 5 →